Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cocrystal Pharma Plans To Extend Phase 2a Influenza Challenge Study With Oral PB2 Inhibitor CC-42344 Due To Low Influenza Infection Among Challenged Participants

Author: Benzinga Newsdesk | December 31, 2024 09:03am

"While CC-42344 showed a favorable safety and tolerability profile, we're disappointed by the low infectivity rate of the challenge influenza strain used in this study. The establishment of robust influenza infection in healthy, uninfected study subjects is critical to determine clinical endpoints for evaluating antiviral molecules. The low infectivity obtained in this study hindered antiviral data analysis," said Sam Lee, Ph.D., Cocrystal's President and co-CEO.

Posted In: COCP


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist